Laminin subunit gamma-2 (LAMC2), for example, is a promising new biomarker which was examined in a large-scale study of over 400 patients across three continents, where it was elevated in pancreatic cancer serum compared with controls and demonstrated a sensitivity that was comparable with CA19-9 (71, 72). This evidence concerns the gene LAMC2 and familial pancreatic carcinoma.